Cui Xiaoxia, Song Peng, Zhang Li
Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China.
Zhongguo Fei Ai Za Zhi. 2019 Jun 20;22(6):355-362. doi: 10.3779/j.issn.1009-3419.2019.06.05.
Small cell lung cancer (SCLC) is a refractory cancer with high degree of malignancy, rapid disease progression, poor prognosis and easy recurrence. In the past 30 years, the traditional treatment of SCLC, mainly chemotherapy and radiotherapy, has not changed significantly, and the effective treatment method for clinical needs is extremely urgent. The rapid development of precision medicine has revealed the molecular biological characteristics of SCLC, so its diagnosis and treatment will into a new era. At present, some studies have shown that anti-angiogenic drugs, immunotherapy and so on have improved the efficacy of SCLC treatment to some extent, and there are more studies on the diagnosis and treatment of SCLC, so a new field of SCLC treatment are coming and bringing more survival benefits to patients. New studies on targeted therapy, anti-angiogenesis drugs and immunotherapy of molecular pathology of SCLC are emerging. This paper reviews the new diagnosis and treatment methods of SCLC to provide new guidance for its clinical treatment. .
小细胞肺癌(SCLC)是一种恶性程度高、疾病进展迅速、预后差且易复发的难治性癌症。在过去30年里,SCLC的传统治疗方法主要是化疗和放疗,没有显著变化,临床急需有效的治疗方法。精准医学的快速发展揭示了SCLC的分子生物学特征,因此其诊断和治疗将进入一个新时代。目前,一些研究表明,抗血管生成药物、免疫疗法等在一定程度上提高了SCLC的治疗效果,并且关于SCLC诊断和治疗的研究越来越多,所以SCLC治疗的新领域即将到来,并为患者带来更多生存益处。关于SCLC分子病理学的靶向治疗、抗血管生成药物和免疫疗法的新研究不断涌现。本文综述SCLC的新诊断和治疗方法,为其临床治疗提供新的指导。